Antihypertensive trials where a GFR fall >−30% is not unequivocally associated with increased risk of CKD or ESKD
| References . | Setting . | Disease associated with hypertension . | No. . | Average baseline kidney function . | Follow-up (average; years) . | Kidney function variation (Δ) . | Interval of observations from baseline . | Subjects experiencing Δ function (%) . | Treatment . |
|---|---|---|---|---|---|---|---|---|---|
| Beddhu et al. [21] | SPRINT | High CV risk | 6715 | GFR 72 UACR <22 | 3.1 | ΔGFR >−30% to GFR <60 mL/min/1.73 m2 | 6 months and whole follow-up | 2.4 | Intensive versus standard SBP lowering |
| ACCORD BP | DM2 | 4733 | GFR 91 UACR <56 | 4.6 | ΔGFR >−30% to GFR <60 mL/min/1.73 m2 | Whole follow-up | 10 | Intensive versus standard SBP lowering | |
| Peralta et al. [22] | SPS3 | Brain lacunar infarcts | 2489 | GFR 80 | 3.2 | ΔGFR >−30% | First year follow-up | 9 | Intensive versus standard SBP lowering |
| Cooper et al. [23] | CORAL | Renal artery stenosis | 359 | GFR 62 UACR <30 | 4.7 | ΔGFR >−30% | 3–6 months | 18 | Medical treatment only |
| References . | Setting . | Disease associated with hypertension . | No. . | Average baseline kidney function . | Follow-up (average; years) . | Kidney function variation (Δ) . | Interval of observations from baseline . | Subjects experiencing Δ function (%) . | Treatment . |
|---|---|---|---|---|---|---|---|---|---|
| Beddhu et al. [21] | SPRINT | High CV risk | 6715 | GFR 72 UACR <22 | 3.1 | ΔGFR >−30% to GFR <60 mL/min/1.73 m2 | 6 months and whole follow-up | 2.4 | Intensive versus standard SBP lowering |
| ACCORD BP | DM2 | 4733 | GFR 91 UACR <56 | 4.6 | ΔGFR >−30% to GFR <60 mL/min/1.73 m2 | Whole follow-up | 10 | Intensive versus standard SBP lowering | |
| Peralta et al. [22] | SPS3 | Brain lacunar infarcts | 2489 | GFR 80 | 3.2 | ΔGFR >−30% | First year follow-up | 9 | Intensive versus standard SBP lowering |
| Cooper et al. [23] | CORAL | Renal artery stenosis | 359 | GFR 62 UACR <30 | 4.7 | ΔGFR >−30% | 3–6 months | 18 | Medical treatment only |
UACR, µg/mg, albuminuria; CORAL, Cardiovascular Outcomes in Renal Atherosclerotic Lesions; SBP, systolic blood pressure; SPS3, small subcortical stroke.
Antihypertensive trials where a GFR fall >−30% is not unequivocally associated with increased risk of CKD or ESKD
| References . | Setting . | Disease associated with hypertension . | No. . | Average baseline kidney function . | Follow-up (average; years) . | Kidney function variation (Δ) . | Interval of observations from baseline . | Subjects experiencing Δ function (%) . | Treatment . |
|---|---|---|---|---|---|---|---|---|---|
| Beddhu et al. [21] | SPRINT | High CV risk | 6715 | GFR 72 UACR <22 | 3.1 | ΔGFR >−30% to GFR <60 mL/min/1.73 m2 | 6 months and whole follow-up | 2.4 | Intensive versus standard SBP lowering |
| ACCORD BP | DM2 | 4733 | GFR 91 UACR <56 | 4.6 | ΔGFR >−30% to GFR <60 mL/min/1.73 m2 | Whole follow-up | 10 | Intensive versus standard SBP lowering | |
| Peralta et al. [22] | SPS3 | Brain lacunar infarcts | 2489 | GFR 80 | 3.2 | ΔGFR >−30% | First year follow-up | 9 | Intensive versus standard SBP lowering |
| Cooper et al. [23] | CORAL | Renal artery stenosis | 359 | GFR 62 UACR <30 | 4.7 | ΔGFR >−30% | 3–6 months | 18 | Medical treatment only |
| References . | Setting . | Disease associated with hypertension . | No. . | Average baseline kidney function . | Follow-up (average; years) . | Kidney function variation (Δ) . | Interval of observations from baseline . | Subjects experiencing Δ function (%) . | Treatment . |
|---|---|---|---|---|---|---|---|---|---|
| Beddhu et al. [21] | SPRINT | High CV risk | 6715 | GFR 72 UACR <22 | 3.1 | ΔGFR >−30% to GFR <60 mL/min/1.73 m2 | 6 months and whole follow-up | 2.4 | Intensive versus standard SBP lowering |
| ACCORD BP | DM2 | 4733 | GFR 91 UACR <56 | 4.6 | ΔGFR >−30% to GFR <60 mL/min/1.73 m2 | Whole follow-up | 10 | Intensive versus standard SBP lowering | |
| Peralta et al. [22] | SPS3 | Brain lacunar infarcts | 2489 | GFR 80 | 3.2 | ΔGFR >−30% | First year follow-up | 9 | Intensive versus standard SBP lowering |
| Cooper et al. [23] | CORAL | Renal artery stenosis | 359 | GFR 62 UACR <30 | 4.7 | ΔGFR >−30% | 3–6 months | 18 | Medical treatment only |
UACR, µg/mg, albuminuria; CORAL, Cardiovascular Outcomes in Renal Atherosclerotic Lesions; SBP, systolic blood pressure; SPS3, small subcortical stroke.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
